Clinical Trials

Find a Trial

Trial Summary

Protocol No.CP-MGAH22-04
Principal InvestigatorMiller, Kathy
PhasePhase III
Age GroupAdult
TitleA Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
DescriptionThe purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and overall survival than patients treated with trastuzumab plus chemotherapy.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Histologically-proven metastatic or locally-advanced relapsed/refractory HER2+ breast cancer
For a full list of participation criteria, please visit
Applicable Disease SitesBreast - Female
Breast - Male
Participating InstitutionsIndiana University (IU)
  • Eskenazi Hospital
  • IU Health North (For use by Cancer Center CTO only)
  • IU Health West (For use by Cancer Center CTO only)
  • Indiana University Hospital / IU Simon Cancer Center
  • Spring Mill Medical Center
Treatment TypeTreatment
ContactCheri A West, RNPhone: 317-278-3021
Pager: 317-312-2375